In 195:5, Maher in England first described the use of subarachnoid injections of phenol solutions in the treatment of intractable pain resulting from cancerl. Since then, numerous investigators have confirmed the efficacy of this procedure for treatment of severe pain problems and for relief of spasticity due to various neuro logic conditions. 2-11 Our experience with the first 43 patients whom we have treated with subarachnoid phenol blocks for pain and spasticity is reported in this article.PROPERTIE S OF PHENOL Carbolic acid or phenol is a weak acid (KA = 1'7 x 10-10) with bactericidal and caustic properties. Phenol is used in various preparations and concentrations as a topical analgesic, antipruritic, disinfectant, or cauterising agent; and is used in injectable form to destroy or attenuate nerve function, and to produce fibrosis about ligaments (prolotherapy). Lipid solutions of phenol dissolved in glycerin or ethyl iodophenylundecylate (Pantopaque)* are less caustic than aqueous phenol solutions. The effect of 5 per cent. lipid solution upon nerve fibres is approximately the same as an 0'1 per cent. aqueous solution.l2 To cause permanent destruction of all nerve fibres, a 25 per cent. lipid-phenol solution is required;' Animal experiments have shown that there is a differential blocking effect of phenol solutions upon the various action potentials of nerve roots. The function of small nerve fibres-the gamma fibres which mediate spasticity and the 'C' fibres which mediate pain-is more severely and more permanently impaired by exposure to various concentrations of phenol than are the larger nerve fibres.12,13 This differential effect of phenol-relief of pain and spasticity with minimum involve ment of voluntary motor activity and sensory perception-is one basis of its unique clinical value. Histologic studies on animals and patients, however, have shown that nerve fibres of all sizes show a similar degree of myelin degeneration following exposure to a phenol solution. Thus, the differential physiologic effect of phenol upon nerve function does not correspond to results of the pathological examin ation.l4,l5.l6 Post-mortem examinations of humans have occasionally shown evi dence of arachnoiditis in the area of phenol application, but no clinical systemic or meningitic reactions (as have been noted following subarachnoid alcohol blocks) have been reported. CLINICAL PROBLEMS AND TREATMENT OFSPASTICITY AND PAIN Spasticity and pain are two major problems in the rehabilitation of patients with injury or disease of the central nervous system. Spasticity itself frequently causes pain. Furthermore, muscle spasticity interferes with movement, predis-* Pantopaque is the Lafayette Pharmaceutical Company trade name for iodophenyl undecylate.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.